Search

Displaying results 3931 - 3940 of 4233 in total
  1. Drug

    Vevorisertib

    go.drugbank.com/drugs/DB21481
    Investigational

    Vevorisertib is under investigation in clinical trial NCT02761694 (Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations

  2. Drug

    Meropenem

    go.drugbank.com/drugs/DB00760
    ApprovedInvestigational

    Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall ...

  3. Drug

    Lefradafiban

    go.drugbank.com/drugs/DB04863
    Investigational

    Lefradafiban is an oral platelet glycoprotein IIb/IIIa receptor antagonist being investigated in the treatment of angina.

  4. Drug

    Arotinolol

    go.drugbank.com/drugs/DB09204
    Investigational

    Arotinolol is an alpha- and beta-receptor blocker developed in Japan. It is a thiopropanolamine with a tertiary butyl moiety. It has been studied for its potential to be an antihypertensive therapy. Artinolol is being developed by Sumito...

  5. Drug

    SVV-001

    go.drugbank.com/drugs/DB06129
    Investigational

    SVV-001 (Seneca Valley Virus) is a novel native picornavirus being developed as a systemically deliverable oncolytic virus for treatment of human cancers with neuroendocrine features.

  6. Drug

    Cyclic GMP

    go.drugbank.com/drugs/DB02315
    Experimental

    It is a cellular regulatory agent and has been described as a second messenger.

  7. Drug

    FINLAY-FR-1

    go.drugbank.com/drugs/DB16524
    Experimental

    FINLAY-FR-1, also known as Soberana 01, is a vaccine candidate for COVID-19 that is being led developmentally by the Finlay Vaccine Institute[L31373].

  8. Drug

    Relugolix

    go.drugbank.com/drugs/DB11853
    ApprovedInvestigational

    [A225761] Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist approved for the treatment of prostate cancer - similar therapies such as [degarelix] require subcutaneous

  9. Drug

    Vadadustat

    go.drugbank.com/drugs/DB12255
    ApprovedInvestigational

    [A244165] The treatment of anemia associated with chronic kidney disease (CKD) has traditionally involved the administration of exogenous erythropoiesis-stimulating agents (ESAs), such as [darbepoetin

  10. Drug

    Olodaterol

    go.drugbank.com/drugs/DB09080
    ApprovedInvestigational

    Treatment with bronchodilators helps to mitigate associated symptoms such as shortness of breath, cough, and sputum production.